About the Academy

A collaborative research training environment

The Ovarian Cancer Academy is a virtual career development and research training platform that consists of Early-Career Investigator/Designated Mentor pairs and two Academy Deans.

OCRP Info Booklet

Academy Highlights


Anti-Tumor Immunity Identified with New Ovarian Cancer Treatment Strategy

Rugang Zhang, Ph.D. finds that a class of drugs known as bromodomain and extraterminal domain (BET) inhibitors could be used to boost anti-tumor immunity and cause T-cells to target the cancer directly while minimizing side effects.

Learn More

Recent Publications

View All
Oct 15, 2016
VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal
Mol Oncol. 2016 Sep 28. PubMed PMID: 27729194
Sep 13, 2016
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Cell Rep. 2016 Sep 13;16(11):2829-37. PubMed PMID: 27626654.
May 27, 2016
A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients
Cancer Causes Control. 2016 May;27(5):661-8. PMID: 27023470.